SCHEMBL19407335

SCHEMBL19407335

COc1c2c(nc3ccccc13)OCC2

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 5/20 0.66
▸ ALDH1A1 P00352 3/20 0.66
▸ POLB P06746 2/20 0.54
▸ ACHE P22303 3/20 0.51
▸ LMNA P02545 2/20 0.48
▸ TSHR P16473 2/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ THPO P40225 1/20 0.48
▸ STAT6 P42226 1/20 0.48
▸ BLM P54132 1/20 0.48
▸ MAPT P10636 3/20 0.43
▸ KDM4E B2RXH2 3/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ EDNRB P24530 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29120936 0.80 ALDH1A1 (1.00) CYP1A2ALDH1A1POLBACHETSHR
SCHEMBL30632945 0.80 ALDH1A1 (1.00) CYP1A2ALDH1A1POLBACHETSHR
SCHEMBL9584702 0.76 ACHE (0.82) CYP1A2ALDH1A1POLBACHELMNA
SCHEMBL28063855 0.74 POLB (0.56) CYP1A2ALDH1A1POLBLMNATSHR
SCHEMBL1408391 0.72 POLB (1.00) ALDH1A1POLBACHELMNATSHR
SCHEMBL28042946 0.69 CYP1A2 (0.79) CYP1A2ALDH1A1POLBLMNATSHR
SCHEMBL10286526 0.69 ACHE (0.65) CYP1A2ALDH1A1POLBACHELMNA
SCHEMBL11842844 0.69 POLB (0.53) CYP1A2ALDH1A1POLBACHETSHR
SCHEMBL9215322 0.68 ACHE (1.00) CYP1A2ALDH1A1ACHELMNATSHR
SCHEMBL10287056 0.68 POLB (0.51) ALDH1A1POLBACHEBLMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186563-B2 Pd(II)-catalyzed enantioselective β-methylene C(sp3)—H bond activation THE SCRIPPS RESEARCH INSTITUTE (US) 2021-11-30 — — US disclosed
US-20190315710-A1 Pd(II)-catalyzed Enantioselective Beta-Methylene C(sp3)–H Bond Activation THE SCRIPPS RESEARCH INSTITUTE 2019-10-17 — — US disclosed
WO-2017165304-A2 Pd(II)-CATALYZED ENANTIOSELECTIVE BETA-METHYLENE C(sp3)-H BOND ACTIVATION THE SCRIPPS RESEARCH INSTITUTE (US) 2017-09-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190315710-A1 Pd(II)-catalyzed Enantioselective Beta-Methylene C(sp3)–H Bond Activation POLQ, AP3D1, AP3S1 CYP1A2 1513/4885ALDH1A1 574/4885POLB 699/4885
US-11186563-B2 Pd(II)-catalyzed enantioselective β-methylene C(sp3)—H bond activation POLQ, AP3D1, AP3S1 CYP1A2 1559/4885ALDH1A1 590/4885POLB 712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback